Of note, a patient with a CHEK2 mutation was diagnosed with a stage IA serous borderline ovarian tumor, a lesion that has been suggested to belong to an ovarian carcinogenesis pathway alternative to the STIC-to-HGSC progression, as previously mentioned. The gene discussed is CHEK2; the disease is borderline ovarian serous tumor.